Bank of America Corp DE lifted its holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) by 224.9% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 865,613 shares of the company's stock after purchasing an additional 599,179 shares during the period. Bank of America Corp DE owned approximately 0.48% of Compass Therapeutics worth $4,579,000 at the end of the most recent reporting period.
Other hedge funds have also made changes to their positions in the company. Russell Investments Group Ltd. increased its stake in Compass Therapeutics by 3,933.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company's stock valued at $27,000 after buying an additional 7,592 shares during the period. Creative Planning purchased a new position in shares of Compass Therapeutics in the 2nd quarter worth $30,000. Strs Ohio purchased a new stake in Compass Therapeutics during the 1st quarter worth $34,000. CIBC Bancorp USA Inc. purchased a new stake in shares of Compass Therapeutics during the third quarter valued at approximately $37,000. Finally, Victory Capital Management Inc. boosted its stake in shares of Compass Therapeutics by 20.6% during the 3rd quarter. Victory Capital Management Inc. now owns 12,652 shares of the company's stock valued at $44,000 after buying an additional 2,164 shares during the last quarter. Hedge funds and other institutional investors own 68.43% of the company's stock.
Compass Therapeutics Price Performance
NASDAQ:CMPX opened at $2.40 on Friday. The company has a market cap of $432.22 million, a P/E ratio of -6.00 and a beta of 0.92. Compass Therapeutics, Inc. has a one year low of $1.61 and a one year high of $6.88. The firm's fifty day moving average price is $2.19 and its two-hundred day moving average price is $3.46.
Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). As a group, equities research analysts expect that Compass Therapeutics, Inc. will post -0.47 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of research firms recently issued reports on CMPX. LADENBURG THALM/SH SH started coverage on Compass Therapeutics in a research report on Wednesday, July 1st. They set a "buy" rating and a $5.00 price objective for the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Compass Therapeutics in a research note on Friday, July 17th. Citigroup reaffirmed a "market outperform" rating on shares of Compass Therapeutics in a report on Thursday, June 4th. Piper Sandler upped their price target on shares of Compass Therapeutics from $4.00 to $6.00 and gave the company an "overweight" rating in a research report on Friday, August 7th. Finally, Wall Street Zen lowered Compass Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $11.77.
Check Out Our Latest Report on CMPX
Compass Therapeutics Company Profile
(
Free Report)
Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.
The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Compass Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Therapeutics wasn't on the list.
While Compass Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
